Previous close | 202.46 |
Open | 201.22 |
Bid | 208.77 x 400 |
Ask | 209.35 x 300 |
Day's range | 199.10 - 210.82 |
52-week range | 189.44 - 319.76 |
Volume | |
Avg. volume | 1,270,188 |
Market cap | 30.415B |
Beta (5Y monthly) | -0.01 |
PE ratio (TTM) | 26.11 |
EPS (TTM) | 8.00 |
Earnings date | 23 Jul 2024 - 29 Jul 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 286.10 |
It's been a good week for Biogen Inc. ( NASDAQ:BIIB ) shareholders, because the company has just released its latest...
Sage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression drug Zurzuvae drives the company's top line.
Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.